Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPR maternal viral suppression with long-acting therapy
PACTR202607711608317Phase 3Not yet recruiting
- Sponsor
- Africa Clinical Research Network
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cabotegravir, lenacapavir and dolutegravir + tenofovir disoproxil fumarate + lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Africa Clinical Research Network. Primary endpoint: Maternal virologic suppression. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cabotegravirlenacapavirdolutegravir + tenofovir disoproxil fumarate + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202607711608317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607711608317.